Apraclonidine for the pharmacologic confirmation of acute Horner syndrome

Apraclonidine is the most widely used pharmacologic agent to confirm Horner syndrome. It is a strong α-2 and a weak α-1 adrenergic agonist and reversal of anisocoria is considered a positive test. The utility of apraclonidine in acute Horner syndrome remains controversial as the exact timing for denervation sensitivity to develop remains unknown. The goal of this study was to describe the use of apraclonidine in the diagnosis of acute Horner syndrome in patients with an unequivocal onset within 7 days.

Source: Journal of the Neurological Sciences - October 14, 2020 Category: Neurology Authors: Michael T.B. Nguyen, Armin Farahvash, Angela Zhang, Jonathan A. Micieli Tags: Clinical short communication Source Type: research